Last reviewed 2026-04-23 · How we verify

Regadenoson central -central

Regadenoson central acts as an adenosine A2A receptor agonist, increasing coronary blood flow.

Regadenoson central acts as an adenosine A2A receptor agonist, increasing coronary blood flow. Used for Nuclear stress test for coronary artery disease.

At a glance

Mechanism of action

Regadenoson central works by stimulating the adenosine A2A receptor, which leads to vasodilation and increased blood flow to the heart. This allows for improved myocardial perfusion and oxygenation, particularly during stress testing. The increased blood flow can help to identify coronary artery disease and other cardiac conditions.

Approved indications

• Nuclear stress test for coronary artery disease

Common side effects

• Headache
• Dizziness
• Nausea

Key clinical trials

• Stress Echo 2030: the Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging
• Perfusion Imaging With Myocardial Contrast Echocardiography in HCM (NA)
• A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT) (PHASE3)
• Evaluation of Myocardial Ischemia Using Standard Single Photon Emission Computed Tomography (SPECT) With Regadenoson and Simultaneous Cardiac Echocardiography
• Regadenoson and Adenosine (PHASE3)
• A Single Center Study to Establish the Imaging Protocol of 99mTc-EC-DG in Evaluating the Presence and Severity of Coronary Artery Disease (CAD) (PHASE2)
• A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.